Acute and persistent responses after H5N1 vaccination in humans
Apps R, Biancotto A, Candia J, Kotliarov Y, Perl S, Cheung F, Farmer R, Mulè M, Rachmaninoff N, Chen J, Martins A, Shi R, Zhou H, Bansal N, Schum P, Olnes M, Milanez-Almeida P, Han K, Sellers B, Cortese M, Hagan T, Rouphael N, Pulendran B, King L, Manischewitz J, Khurana S, Golding H, van der Most R, Dickler H, Germain R, Schwartzberg P, Tsang J. Acute and persistent responses after H5N1 vaccination in humans. Cell Reports 2024, 43: 114706. PMID: 39235945, DOI: 10.1016/j.celrep.2024.114706.Peer-Reviewed Original ResearchH5N1 influenza vaccineImpact vaccine responsesTime pointsAdjuvant AS03H5N1 vaccineInfluenza vaccineT cellsVaccine responseVaccinated cohortHigh antibody respondersImmune stateVaccine antigensMultiple time pointsSingle-cell profilingInitial vaccinationSystems immunologyVaccinePersistent responseSurface proteinsCell type-specific signaturesChromatin accessibilityTranscription factorsH5N1DaysAS03Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus
Khurana S, King L, Manischewitz J, Posadas O, Mishra A, Liu D, Beigel J, Rappuoli R, Tsang J, Golding H. Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus. Nature Medicine 2024, 30: 2771-2776. PMID: 39013430, DOI: 10.1038/s41591-024-03189-y.Peer-Reviewed Original ResearchCross-neutralizing antibodiesH5N1 vaccineNeutralizing antibody responsesVaccination of adultsDevelopment of effective vaccinesGlobal public health threatHPAI H5N1Influenza virusSeroconversion ratesH5N1Neutralizing antibodiesCross-reactive bindingPublic health threatLicensed vaccinesHemagglutination inhibitionPublic health priorityAntibody responseEffective vaccineHPAIVaccineAntibodiesDoseHealth priorityVirusHealth threat